Current evidence does not support the routine use of BoNT-A as a first-line treatment for TMDs overall, and BoNT-A may represent an adjunctive or second-line option for selected patients with myogenous TMD, localized myofascial pain, or marked masticatory muscle hyperactivity who do not adequately respond to conventional noninvasive treatment.
Abstract
Temporomandibular disorders (TMDs) represent a heterogeneous group of conditions, including myogenous and arthrogenous, with a significant impact on quality of life. Botulinum toxin type A (BoNT-A) has been proposed as a therapeutic option, particularly for patients with refractory myogenous TMD and bruxism. This systematic review aimed to evaluate the clinical effectiveness of BoNT-A in the management of TMDs overall and bruxism, with particular focus on myogenous TMDs compared to placebo and non-surgical treatments. RCTs published between 2020 and 2025 were identified through PubMed, Scopus, and Google Scholar. Overall, 15 RCTs involving 797 participants were included. The available evidence suggests potential benefits of BoNT-A, particularly in patients with localized myofascial pain, myogenous TMD, or marked masticatory muscle hyperactivity. Interpretation of the findings is limited by substantial heterogeneity in treatment protocols, toxin dosage, diagnostic criteria, outcome measures, and follow-up duration. Current evidence does not support the routine use of BoNT-A as a first-line treatment for TMDs overall. Instead, BoNT-A may represent an adjunctive or second-line option for selected patients with myogenous TMD, localized myofascial pain, or marked masticatory muscle hyperactivity who do not adequately respond to conventional noninvasive treatment. Larger and methodologically rigorous RCTs are needed to establish appropriate indications, duration of treatment effects, and long-term safety across different TMD subtypes.
Background Botulinum toxin type A (BoNT-A) has been increasingly investigated for persistent myogenic temporomandibular disorders (TMDs), particularly when conservative therapies provide insufficient symptom control. However, variability in patient selection, injection protocols, outcomes, and safety reporting complica...
Marines Vega Sanchez, Luis Chauca-Bajaña, Francisco Córdova et al.· Journal of Oral Biology and...· 0 citations
Temporomandibular disorders (TMDs) are heterogeneous musculoskeletal conditions frequently characterized by pain, impaired mandibular function, and reduced quality of life. Botulinum neurotoxin type A (BoNT-A) has emerged as a potential therapeutic option, particularly for persistent myogenous TMDs associated with mast...
Martina Ferrillo, C. Curci, Dario Calafiore et al.· Toxins· 0 citations
Background/Objectives: The therapeutic use of local anesthetics has been discussed in several musculoskeletal pain conditions, but its role in myogenous temporomandibular disorders (TMDs) remains unclear. This study evaluated clinical outcomes after a therapeutic local anesthetic injection protocol in patients with chr...
G. N. Hasanoglu Erbasar, O. Odabaşı, Sercan Dolanbay et al.· Journal of Clinical Medicine· 0 citations
MT and TE are effective strategies for reducing pain in subjects with TMDs and should be used as first-line interventions before more invasive treatments; the combination of dry needling and manual therapy appears to be the most effective approach.
A. Alvisi, A. Casalini, L. Mammana et al.· medRxiv· 0 citations
Therapeutic ultrasound may reduce pain and improve mandibular function in patients with temporomandibular disorders, particularly as an adjunct to multimodal rehabilitation; however, the certainty of the evidence is very low for pain and low for mandibular function, pressure pain threshold and quality of life/disabilit...
Xiao-Feng Zhou, Da-Wei Wang, Fen Jiang et al.· Ultrasound in Medicine and B...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.